Form 4: Akero Therapeutics Senior VP Sells Shares to Cover Tax Obligations

Akero Therapeutics' Senior VP, Commercial Strategy, Patrick Lamy, sold 919 shares of common stock at a weighted-average price of $53.999 to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Patrick Lamy, Senior VP, Commercial Strategy at Akero Therapeutics, Inc. (AKRO), reported a transaction on June 10, 2025.
• The transaction involved the disposition of 919 shares of Common Stock.
• The shares were sold at a weighted-average price of $53.999 per share, with prices ranging from $53.93 to $54.00.
• This sale was a 'sell-to-cover' transaction, executed automatically to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
• Following this transaction, Patrick Lamy beneficially owns 32,573 shares of Common Stock directly.

Sentiment

Score: 5

Explanation: The transaction is a routine 'sell-to-cover' to satisfy tax withholding obligations upon vesting of restricted stock units, not indicative of discretionary selling or a change in management's outlook, thus having a neutral sentiment.

Future Outlook

NA

Management Comments

• The sale of shares represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units.
• The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person.
• Such sales were automatic and not at the discretion of the Reporting Person.

Industry Context

NA

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a routine, non-discretionary sale for tax purposes, not indicative of a change in management's confidence or company fundamentals.

Key Dates

Recommendation

Keywords

Akero Therapeutics, AKRO, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, Patrick Lamy